| Literature DB >> 32961669 |
Christina N Katsagoni1,2, Eleftheria Papachristou1, Amalia Sidossis3, Labros Sidossis1,2.
Abstract
Non-alcoholic fatty liver disease (NAFLD) affects 5.5-10.3% of children worldwide, while in obese individuals, it increases to almost 34%. Pediatric NAFLD is consistently associated with metabolic syndrome and insulin resistance. As no pharmacological agents exist for the treatment of NAFLD, lifestyle modifications remain the only therapy. However, as not all overweight/obese children have NAFLD, high-quality data, focused exclusively on NAFLD population are needed. Therefore, the present systematic review assessed the efficacy of lifestyle (diet or exercise) based on randomized controlled clinical trials (RCTs) on liver, anthropometric, glucose, and lipid parameters in children, with imaging or biopsy-proven NAFLD. In general, the results were inconclusive and therefore no specific recommendations could be drawn. In most studies, differences were derived from within group comparisons, which are known to be highly misleading. However, both low-carbohydrate and low-fat diets could benefit liver outcomes, as long as weight loss is achieved, but not necessary glucose and lipid parameters. No RCTs were found on exercise alone, as compared to no intervention on pediatric NAFLD. Concerning diet plus exercise interventions, all studies led to improvements in liver outcomes accompanied with weight loss. Resolution of NAFLD was found in considerably high percentages, while improvements were also seen in glucose but were modest in lipid parameters.Entities:
Keywords: NAFLD; childhood obesity; children; diet; insulin resistance; lifestyle; non-alcoholic fatty liver disease
Mesh:
Year: 2020 PMID: 32961669 PMCID: PMC7551480 DOI: 10.3390/nu12092864
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 5.717
Figure 1Flowchart of the included studies.
Characteristic of interventions based on diet.
| Author [ref] | Journal | Country | Sample (n) | Intervention Group | Control Group | Nafld Definition | Age (y) (mean ± SD) | Sex (boys) | Type of Intervention | Dura-tion | Primary Outcomes | Secontary Outcomes | Completion Rates |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
| |||||||||||||
| Vos et al, 2009 [ | Arch Pediatr Adolesc Med | USA | 10 | 6 (Low-fructose group) | 4 (Low-fat group) | Liver biopsy or serology and US | Low-fructose group: 13.3 ± 0.65. Low-fat group: 12.5 ± 1.0. | NR | Low-fructose group: Diet with eliminated sugar containing beverages, fruit juice and food items with high-fructose corn syrup (HFCS) as one of the top 5 ingredients on the label. Low-fat group: Diet based on the American Heart Association recommendations. | 6mo | Oxidatized LDL-C | Changes in BMI z-score, BP, AST, ALT, HDL-C, LDL-C, TCHOL, TG, Urinary isoprostanes | NR |
| Ramon-Krauel et al, 2013 [ | Child Obes. | USA | 17 | 8 (Low-glycemic-load group) | 9 (Low-fat diet group) | ≥9% liver fat content assessed by MRS | Low-GL group: 11.8 ± 3.0. Low-fat group: 13.8 ± 3.2. | Low-glycemic load group: 7. Low-fat group: 7. | Low-GL group: Ad libitum diet. C:F:P: 40:35-40:20–25. Low to moderate GL carbohydrate food items. Low-fat group: Ad libitum diet. C:F:P:55-60:20:20–25. Vitamin supplements provided in both groups. | 6mo | Intrahepatic tiglyceride content (IHTC) | Height, Body weight, waist/abdomen/hip circumferences, BP, TCHOL, HDL-C, LDL-C, TG, ALT, AST, Glucose, Insulin | 94% |
| Jin et al, 2014 [ | Nutrients | USA | 24 | 13 (Glucose beverages group) | 11 (Fructose beverages group) | IHTG content >8% assessed by MRS | Glucose beverages group: 14.2 ± 0.88. Fructose beverages group: 13.0 ± 0.71. | Glucose beverages group: 3. Fructose beverages group: 8. | Glucose beverages group: Consumption of 3 servings (8 fl oz bottles) of glucose-containing beverages daily. No diet or physical activity modification. Fructose beverages group: onsumption of 3 servings (8 fl oz bottles) of fructose-containing beverages daily. No diet or physical activity modification. | 4wks | Body weight, Hepatic fat (%), ALT, AST, TG, FFAs, Glucose, Insulin, hs-CRP, LDL-C, lag time, oxLDL, PAI-1 | NR | 91.7% |
| Agustini et al, 2019 [ | Med J Indones | Indo-nesia | 32 | 16 (low-energy, GI, and fat) | 16 (nutrition education) | US-diagnosed fatty liver | 12-14yrs | 24 | Intervention group: Nutrition education and lunch diet (lunch box provided consisted of low-fat, <25% of total calories, low cholesterol, <300 mg/day, and low-GI diet). Control group: Nutrition education | 12wks | FBG, Insulin, Body weight, Height, Dietary intake | NR | 100% |
| Schwimmer et al, 2019 [ | JAMA | USA | 40 | 20 (Low-sugar diet group) | 20 (Usual diet group) | ≥10% of IHTG measured by MRI-PDFF and ALT≥45U/L | 11-16yrs old. Low-sugar diet group: 12.8 ± 1.87. Usual diet group: 13.4 ± 1.9. | 40 | Low-sugar diet group: Avoidance of sugar-containing foods and drinks. Ad libitum diet with >3% of free sugars. Usual diet group: maintainance of their habitual diet. | 8wks | Percentage of hepatic steatosis | Insulin resistance; ALT, AST, GGT, FBG, Insulin, TCHOL, LDL-C, HDL-C, TG, sweetness perception testing diet adherence, adverse events. | 100% |
| Goss et al, 2020 [ | Pediatr Obes. | USA | 32 | 16 (CRD-group) | 16 (FRD-group) | ALT>45IU/L and/or indication of echogenic liver via US | 9–17 yrs old. CRD-group: 14.5 ± 2.6. FRD-group: 14.2 ± 2.1. | CRD-group: 9. RRD-group: 7. | CRD-group: Diet aiming at minimizing the intake of refined CHO. Meal plans provided. C:F:P:≤25:≥50:25. FRD-group: Diet promoting low-energy, high-quality foods, based on based on the USDA MyPlate Daily Food Plan. Meal plans provided. C:F:P:55:20:25. | 8wks | Hepatic fat content, Body composition, TCHOL, LDL-C, HDL-C, TG, Glucose, Insulin, CRP, ALT, AST, GGT | NR | 78% |
Abbreviations: ALT—alanine aminotransferase; AST—aspartate aminotransferase; BMI—body mass index; BP—blood pressure; C:P:F—carbohydrates:protein:fats; CRD—carbohydrate-restricted diet; FBG—fasting blood glucose; FFAs—free-fatty acids; FRD—fat-restricted diet; GL—glycemic load; GGT—γ- glutamyl transferase; HDL-C—high-density lipoprotein cholesterol; hs-CRP—high sensitivity C-reactive protein; IHTG—intrahepatic triglycerides; LDL-C—low-density lipoprotein cholesterol; MRI-PDFF—magnetic resonance imaging (MRI) proton density fat fraction (PDFF); NAFLD—non-alcoholic fatty liver disease; oxLDL—oxidazide LDL; RCT—randomized clinical trial; TCHOL—total cholesterol; TG—triglycerides; and US—ultrasound.
Characteristics based on lifestyle (i.e., diet plus exercise) and exercise-focused interventions.
| Author [ref] | Journal | Country | Sample (n) | Intervention Group | Control Group | Nafld definition | Age (y) (mean ± SD) | Sex (boys) | Type of Intervention | Duration | Primary Outcomes | Secontary Outcomes | Completion Rates |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
| |||||||||||||
| Wang et al, 2008 [ | World J Gastroenterol | China | 57 | 19 (Group 2) | 38 (Group 1) | Liver fatty infiltration in US, abnormal ALT (1.5 times <50IU/L) | Group 1: 14.04 ± 1.8. Group 2: 13.4 ± 2.5. | Group 1: 26 Group 2: 13 | Group 1: no intervention; Group 2: Aerobic exercise: 3 hrs of free exercise daily; Diet: Low-calorie (↓ 250 kcal)- high carbohydrate (50%)- low fat (10%) diet. | 1mo | Height, Body weight, FBG, insulin, ALT, AST, TG, TCHOL, fatty liver indication in US | - | NR |
| Koot et al, 2015 [ | International Journal of Obesity | The Netherlands | 55 | 23 at Inpatient group & 21 at Ambulatory group | 18 (Usual care group) | IHTG > 1.8% assesed by 1H-MRS | Inpatient treatment group: 14.9 ± 2.5. Ambulatory treatment group: 14.4 ± 2.1. Usual care group: 14.7 ± 2.4 | Inpatient treatment group: 10. Ambulatory treatment group: 13. Usual care group: 10 | Inpatient treatment group: High intensity aerobic exercise 4 days per wk (30–60min each); Nutrition (focused on dietary quality) and behavior (self-regulation, self-awareness, goal setting) modification sessions at weekly base (60min each). Ambulatory treatment group: Each session consisted of 60min high intensity exercise (plus advice to engage in exercise 3times/wk), an 1 hr-educational program and a 30min nutritional program Control group: Usual care | 6mo & 18mo follow-up | 1H-MRS determined liver steatosis, ALT | Length, Body weight, Waist circumference, BP, GGT, Insulin, HD-CL, LDL-C, Glucose | 91% (6mo) and 80% (24mo) |
| Chan et al, 2018 [ | Int J Obes (Lond) | China | 52 | 26 | 26 | IHTG≥5% measured by 1H-MRS | Intervention group: 15.3 ± 3.4. Control group: 13.8 ± 5.3. | Intervention group: 16. Control group: 17. | Intervention group: Individualized menu plan (balanced diet with a relative increase in protein) provided by a dietitian and exercise plan aiming at 30min aerobic exercise 2-3times/wk. Control group: Usual diet and exercise advice (↓ high-glycemic index carbohydrateand animal fat, and exercise for at least 2-3 times/wk for 30min per session. | 16wks & 52wks follow-up | Changes in IHTC assessed by 1H-MRS at 16 wks | Maintanance of changes in IHTC at 52 wks, FBG, Lipid profile, ALT, AST, Serum insulin, Anthropometric measurements | 80.8% |
|
| |||||||||||||
| de Piano et al, 2012 [ | Eur J Gastroenterol Hepatol | Brazil | 28 | 14 aerobic training plus resistance training group (AT+RT) | 14 aerobic training group (AT) | US-diagnosed fatty liver | 16.48 ± 1.42 | 27 | AT+RT group: Aerobic and resistance exercise training 3 times/wk for 1 h each time (30min aerobic training: running on treadmill, and 30min resistance trianing). AT-group: Aerobic exercise training 3 times/wk for 1 h each. Psychological intervention, Nutritional intervention (Nutritional education on a balanced diet), clinical evaluation once a week for both groups. | 1yr | Body weight, Height, Body composition, FBG, Insulin, TCHOL, LDL-C, VLDL, HDL-C, TG, AST, ALT, GGT, Adipokines, Neuropeptides, | NR | NR |
Abbreviations: ALT—alanine aminotransferase; AST—Aspartate aminotransferase; BMI—body mass index; GGT—γ- glutamyl transferase; HDL-C—high-density lipoprotein cholesterol; IHTG—intrahepatic triglycerides; LDL-C—low-density lipoprotein cholesterol; 1H-MRS—proton magnetic resonance spectroscopy; NAFLD—non-alcoholic fatty liver disease; RCT—randomized clinical trial; TCHOL—total cholesterol; TG—triglycerides; and US—ultrasound.